Limitations on Reproductive Rights Makes Agonizing Decisions Even Harder for Pregnant Women With CancerApril 25th 2023
Even before the Dobbs ruling overturned country-wide reproductive rights, the oncology field was already facing a dearth of maternal care access challenges.
Expert: Reproductive Rights Legislation Impacts Women’s Medical Options When Diagnosed With Cancer While PregnantApril 25th 2023
Limitations on a woman’s options when pregnant and diagnosed with cancer can directly impact her ability to save her own life and preserve her fertility for future pregnancies.
Tafasitamab Combination Provides Prolonged, Durable Response in Patients with Aggressive DLBCLApril 17th 2023
According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.
Personalized mRNA Cancer Vaccine With Pembrolizumab Significantly Prolonged Recurrence Free Survival in Resected High-risk MelanomaApril 17th 2023
These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.
Pembrolizumab Plus Gemcitabine/Cisplatin Provided Significant Improvement in OS in Advanced Biliary Tract CancerApril 16th 2023
These data support using this combination therapy as a new first-line treatment option in patients with previously untreated metastatic or unresectable BTC.
Novartis Releases Positive Phase 1b/2 Clinical Data for JDQ443 for Treatment of NSCLCApril 14th 2022
The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.
Pfizer’s Lorbrena for Treatment of NSCLC Shows Positive Data in Phase 3 TrialApril 14th 2022
Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).
Rucaparib Shows Efficacy Across Tumors Associated With Different Genetic AlterationsApril 11th 2022
Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.